Focus on the BIG picture.
Thursday, Apr 23, 2026
Outside the box.
US CDC blocks publication of internal report showing COVID-19 vaccines reduce hospital visits
Agency decision halts release of study finding vaccines cut emergency care and hospitalisation risk by around 50%, prompting concerns over scientific review and political influence
The US Centers for Disease Control and Prevention (CDC) has decided not to publish an internal report that found COVID-19 vaccination significantly reduced the likelihood of emergency department visits and hospitalisations among healthy adults during the most recent winter season.
The unpublished analysis, which had already passed internal scientific review and was originally scheduled for release in the CDC’s Morbidity and Mortality Weekly Report in March, concluded that vaccinated individuals experienced roughly a 50% reduction in COVID-related hospital admissions and emergency care compared with unvaccinated individuals.
According to multiple people familiar with the process, publication was first delayed after senior leadership raised concerns about the statistical methodology used to estimate vaccine effectiveness.
The approach in question, a widely used observational “test-negative” design, is routinely employed in vaccine effectiveness research, including studies published in leading medical journals.
Following the initial delay, a further decision was taken to block publication entirely, despite the report having cleared standard scientific review procedures.
Officials from the Department of Health and Human Services confirmed that concerns about methodological interpretation were cited as the basis for the decision, stating that the manuscript did not meet requirements for publication in its current form.
The report’s findings have drawn attention because they align with a broader body of evidence showing that COVID-19 vaccines continue to reduce the severity of illness, particularly in preventing hospitalisation even as population immunity has evolved over time.
The decision has prompted debate among current and former public health officials, some of whom argue that the handling of the study risks limiting transparency around vaccine performance data.
Others maintain that internal review standards exist precisely to ensure that only methodologically robust findings are released through official channels.
The episode comes amid wider policy discussions in Washington over the direction of federal vaccine guidance and the role of scientific advisory processes within public health agencies.
No revised timeline for publication has been announced.
The unpublished analysis, which had already passed internal scientific review and was originally scheduled for release in the CDC’s Morbidity and Mortality Weekly Report in March, concluded that vaccinated individuals experienced roughly a 50% reduction in COVID-related hospital admissions and emergency care compared with unvaccinated individuals.
According to multiple people familiar with the process, publication was first delayed after senior leadership raised concerns about the statistical methodology used to estimate vaccine effectiveness.
The approach in question, a widely used observational “test-negative” design, is routinely employed in vaccine effectiveness research, including studies published in leading medical journals.
Following the initial delay, a further decision was taken to block publication entirely, despite the report having cleared standard scientific review procedures.
Officials from the Department of Health and Human Services confirmed that concerns about methodological interpretation were cited as the basis for the decision, stating that the manuscript did not meet requirements for publication in its current form.
The report’s findings have drawn attention because they align with a broader body of evidence showing that COVID-19 vaccines continue to reduce the severity of illness, particularly in preventing hospitalisation even as population immunity has evolved over time.
The decision has prompted debate among current and former public health officials, some of whom argue that the handling of the study risks limiting transparency around vaccine performance data.
Others maintain that internal review standards exist precisely to ensure that only methodologically robust findings are released through official channels.
The episode comes amid wider policy discussions in Washington over the direction of federal vaccine guidance and the role of scientific advisory processes within public health agencies.
No revised timeline for publication has been announced.
